Status:
COMPLETED
Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
Lead Sponsor:
Sanofi
Conditions:
Smoking
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotin...
Eligibility Criteria
Inclusion
- Outpatients over the legal age smoking at least 10 cigarettes per day for at least 2 months
Exclusion
- Insufficient level of motivation
- Another participant in the household
- Patients with current psychotic disorder or major depressive disorder
- The investigator will evaluate whether there are other reasons why a patient may not participate.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
602 Patients enrolled
Trial Details
Trial ID
NCT00356967
Start Date
June 1 2006
End Date
June 1 2007
Last Update
December 19 2008
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Diegem, Belgium
2
Sanofi-Aventis Administrative Office
Hørsholm, Denmark
3
Sanofi-Aventis Administrative Office
Paris, France
4
Sanofi-Aventis Administrative Office
Lysaker, Norway